Summary
Merck has announced its plans to acquire Terns Pharmaceuticals for $6.7 billion, in a move to bolster its oncology portfolio. The deal includes Terns’ lead drug candidate, TRN-823, which is being developed for the treatment of acute myeloid leukemia (AML). The acquisition is expected to close in the third quarter of 2021.

Access impact
The acquisition of Terns Pharmaceuticals by Merck has significant implications for pricing, reimbursement, and health technology assessment (HTA) for TRN-823, if it receives regulatory approval. As a differentiated drug candidate for AML, it has the potential to command a high price and may face challenges in gaining reimbursement approval. The acquisition also highlights Merck’s commitment to expanding its oncology portfolio through strategic acquisitions.

Top-3 domain lens
Clinical Effectiveness
TRN-823 has shown promising results in early-stage clinical trials for the treatment of AML, a difficult-to-treat cancer. If approved, it has the potential to improve clinical outcomes for AML patients, which may increase its value and impact pricing and reimbursement decisions.

Cost-Effectiveness
The high cost of developing and acquiring TRN-823 may result in a high price for the drug, which could affect its cost-effectiveness and affordability for patients and payers. This may be a key consideration in pricing and reimbursement decisions.

Safety and Tolerability
TRN-823 has shown a favorable safety and tolerability profile in clinical trials, which may be a positive factor in pricing and reimbursement decisions. However, as the drug is still in early stages of development, further safety data will need to be collected and evaluated.

Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug

CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list

Source
source: https://www.biopharmadive.com/news/merck-terns-acquire-deal-leukemia-drug/815637/